glucose utilization

BM152054 is a potent PPARγ ligand that induces glucose utilization in peripheral tissues by enhancing insulin action.

Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.

L-(+)-Arabinose selectively inhibits intestinal sucrase in a non-competitive manner, thereby preventing glucose elevation induced by sucrose intake.

Sinapinic Acid (Synapoic acid) protects the rat liver from CCl4-induced inflammation, most likely by acting as a free radical scavenger and modulator of NF-κB p65 activation and proinflammatory cytokine expression. Sinapic acid with antioxidant role protects cardiac cells and its functions from I R induced oxidative stress. Sinapic acid is a potentially useful agent for the protection against liver fibrosis and cirrhosis. Sinapic acid prevents the alterations in the levels of lipids and lipoproteins by virtue of its anti-lipidaemic effect in isoproterenol induced myocardial infarcted rats. Sinapic acid ameliorates hyperglycemia through PLC-PKC signals to enhance the glucose utilization in diabetic rats.

D-mannoheptose is the main non-structural carbohydrate in avocado. D-mannoheptose is a specific inhibitor of D-glucose phosphorylation. D-mannoheptose can prevent the release of insulin and the utilization of carbohydrates in rats.

Clorsulon (L631529) is utilized for the treatment of Fasciola hepatica infections in calves and sheep.

Trimetazidine, an anti-ischemic (anti-anginal) metabolic agent, could improve myocardial glucose utilization through inhibition of long-chain 3-ketoacyl CoA thiolase activity and results in a reduction in fatty acid oxidation and a stimulation of glucose

CHIR-98014 (CT98014) is a selective GSK3 inhibitor; potentiate insulin activation of glucose transport and utilization in vitro and in vivo.

3-Iodothyronamine is derived from the deiodination and decarboxylation of endogenous thyroxine. It activates the G protein-coupled receptor known as trace amine-associated receptor 1 at nanomolar concentrations whereupon it rapidly influences thyroid hormone actions including body temperature, heart rate, and cardiac output. It has also been reported to function in controlling lipid and glucose utilization, hormonal secretion, and neuronal function, and has been considered for use in chemically-induced hibernation for medical purposes.

yGsy2p-IN-H23 is a potent, first-in-class inhibitor specifically designed to target yeast glycogen synthase 2 (yGsy2p). It demonstrates an IC50 value of 875 μM for human glycogen synthase 1 (hGYS1). This compound binds precisely within the uridine diphosphate glucose (UDPG) binding pocket of yGsy2p. Its utilization in research primarily focuses on studying glycogen storage diseases (GSDs).

Ritivixibat is an ileal bile acid transporter (IBAT) inhibitor and bile acid modulator. It is utilized in research related to cardiovascular diseases, fatty acid metabolism disorders, glucose utilization abnormalities, gastrointestinal conditions, and liver diseases.

Trimetazidine-d8 Dihydrochloride is a deuterated compound of Trimetazidine Dihydrochloride. Trimetazidine Dihydrochloride has a CAS number of 13171-25-0. Trimetazidine dihydrochloride can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.